



JAMA Health Forum. 2023 May; 4(5): e231080.

PMCID: PMC10199347

Published online 2023 May 19. doi: 10.1001/jamahealthforum.2023.1080:

PMID: [37204803](#)

10.1001/jamahealthforum.2023.1080

Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids

[Anneke L. Claypool](#), PhD,¹ [Catherine DiGennaro](#), BA,¹ [W. Alton Russell](#), PhD,^{1,2} [Melike F. Yildirim](#), PhD,¹ [Alan F. Zhang](#),¹ [Zuri Reid](#),¹ [Erin J. Stringfellow](#), PhD,¹ [Benjamin Bearnot](#), MD,³ [Bruce R. Schackman](#), PhD,⁴ [Keith Humphreys](#), PhD,⁵ and [Mohammad S. Jalali](#), PhD^{1,6}

¹Massachusetts General Hospital Institute for Technology Assessment, Harvard Medical School, Boston²School of Population and Global Health, McGill University, Montreal, Quebec, Canada³Division of General Internal Medicine, Massachusetts General Hospital, Boston⁴Department of Population Health Sciences, Weill Cornell Medical College, New York, New York⁵Veterans Affairs and Stanford University Medical Centers, Palo Alto, California⁶MIT Sloan School of Management, Cambridge, Massachusetts

Corresponding author.

Article Information

Accepted for Publication: March 26, 2023.**Published:** May 19, 2023. doi:10.1001/jamahealthforum.2023.1080

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2023 Claypool AL et al. *JAMA Health Forum*.

Corresponding Author: Mohammad S. Jalali, PhD, 101 Merrimac St, Room 1037, Boston, MA 02114 (msjalali@mgh.harvard.edu).

Author Contributions: Drs Claypool and Jalali had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Claypool, DiGennaro, Russell, Yildirim, Zhang, Bearnot, Humphreys, Jalali.

Acquisition, analysis, or interpretation of data: Claypool, DiGennaro, Russell, Zhang, Reid, Stringfellow, Schackman, Jalali.

Drafting of the manuscript: Claypool, Yildirim.

Critical revision of the manuscript for important intellectual content: Claypool, DiGennaro, Russell, Zhang, Reid, Stringfellow, Bearnot, Schackman, Humphreys, Jalali.

Statistical analysis: Claypool, DiGennaro, Russell, Yildirim, Jalali.

Obtained funding: Stringfellow, Jalali.

Administrative, technical, or material support: Claypool, Stringfellow, Humphreys, Jalali.

Supervision: Bearnot, Jalali.

Conflict of Interest Disclosures: All authors reported grants from the US Food and Drug Administration during the conduct of the study. No other disclosures were reported.

Funding/Support: This work was supported in part by the FDA (grant U01FD007064). Dr Humphreys was supported by a Senior Research Career Scientist award from the Veterans Affairs Health Services Research and Development Service.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: This article reflects the views of the authors and should not be construed to represent the views or policies of the FDA or the US Department of Health and Human Services.

Data Sharing Statement: See [Supplement 2](#).

Additional Contributions: We thank these individuals for their insights and comments on our analysis or earlier versions of this report: Yuhua Bao, PhD, Elizabeth Beaulieu, PhD, Huiru Dong, PhD, Sara Eggers, PhD, Emily Ewing, MPP, Lukas Glos, MA, Jack Homer, PhD, Reza Kazemi, PhD, Nazanin Khatami, PhD, Tse Yang Lim, PhD, Jake Morgan, PhD, Rosalie Pacula, PhD, Andreas Schick, PhD, Carolina Vivas-Valencia, PhD, and Wayne Wakeland, PhD. They were not compensated for their contributions.

Received 2022 Sep 15; Accepted 2023 Mar 26.

[Copyright](#) 2023 Claypool AL et al. *JAMA Health Forum*.

This is an open access article distributed under the terms of the CC-BY License.

Key Points

Question

Are interventions to increase buprenorphine treatment initiation, duration, and capacity for treating opioid use disorder cost-effective?

Findings

In this quality and economic evaluation of modeled interventions to increase buprenorphine treatment initiation, duration, and capacity, we projected health outcomes and costs of 5 interventions and their combinations. This study found that a portfolio of interventions, including contingency management, hub-and-spoke clinician training, initiation of buprenorphine treatment in the emergency department, and telehealth, was the preferred strategy for a range of generally accepted willingness-to-pay thresholds.

Meaning

The findings of this study suggest that interventions that increase buprenorphine treatment duration concurrently with treatment capacity are the most cost-effective and have the largest association with reducing overdose deaths.

Abstract

Importance

Buprenorphine is an effective and cost-effective medication to treat opioid use disorder (OUD), but is not readily available to many people with OUD in the US. The current cost-effectiveness literature does not consider interventions that concurrently increase buprenorphine initiation, duration, and capacity.

Objective

To conduct a cost-effectiveness analysis and compare interventions associated with increased buprenorphine treatment initiation, duration, and capacity.

Design and Setting

This study modeled the effects of 5 interventions individually and in combination using SOURCE, a recent system dynamics model of prescription opioid and illicit opioid use, treatment, and remission, calibrated to US data from 1999 to 2020. The analysis was run during a 12-year time horizon from 2021 to 2032, with lifetime follow-up. A probabilistic sensitivity analysis on intervention effectiveness and costs was conducted. Analyses were performed from April 2021 through March 2023. Modeled participants included people with opioid misuse and OUD in the US.

Interventions

Interventions included emergency department buprenorphine initiation, contingency management, psychotherapy, telehealth, and expansion of hub-and-spoke narcotic treatment programs, individually and in combination.

Main Outcomes and Measures

Total national opioid overdose deaths, quality-adjusted life years (QALYs) gained, and costs from the societal and health care perspective.

Results

Projections showed that contingency management expansion would avert 3530 opioid overdose deaths over 12 years, more than any other single-intervention strategy. Interventions that increased buprenorphine treatment duration initially were associated with an increased number of opioid overdose deaths in the absence of expanded treatment capacity. With an incremental cost-effectiveness ratio of \$19 381

per QALY gained (2021 USD), the strategy that expanded contingency management, hub-and-spoke training, emergency department initiation, and telehealth was the preferred strategy for any willingness-to-pay threshold from \$20 000 to \$200 000/QALY gained, as it was associated with increased treatment duration and capacity simultaneously.

Conclusion and Relevance

This modeling analysis simulated the effects of implementing several intervention strategies across the buprenorphine cascade of care and found that strategies that were concurrently associated with increased buprenorphine treatment initiation, duration, and capacity were cost-effective.

This economic evaluation study includes a cost-effectiveness analysis and compares interventions associated with increased buprenorphine treatment initiation, duration, and capacity.

Introduction

The opioid crisis remains a major public health challenge in the US. Between 1999 and 2020, overdose deaths involving opioids surpassed 564 000,¹ with a record 75 673 opioid overdose deaths (OODs) in 2021.² As of 2019, about 1.4 million people had opioid use disorder (OUD),³ and only an estimated 34.5% received OUD treatment that year.⁴ One effective way to reduce fatal opioid overdoses is to increase the uptake and duration of medication treatment for OUD (MOUD), including buprenorphine.⁵

Buprenorphine has the potential to be expanded, as it can be administered outside of specialty outpatient facilities and is cost-effective.⁶ Several local-level and state-level interventions have been associated with improved buprenorphine initiation (ie, the number initiating treatment), duration (ie, average length of treatment), and capacity (ie, the number of patients that available prescribers can treat). For example, making buprenorphine available in the emergency department is associated with increased initiation^{7,8}; contingency management, psychotherapy, and telehealth are associated with increased duration⁹; and hub-and-spoke networks are associated with increased capacity.¹⁰

Prior analyses estimated that buprenorphine treatment is effective, so expanding its use could be associated with large health benefits and reduced mortality.^{9,11,12,13,14} However, studies have not considered how increases in buprenorphine use may affect capacity and how limited capacity may affect buprenorphine effectiveness and cost-effectiveness. Recent regulatory changes may expand capacity by increasing the number of buprenorphine prescribers. Until 2021, physicians and other eligible health care clinicians in the US were required to complete at least 8 hours of training to obtain a waiver allowing them to prescribe buprenorphine to 30 patients or fewer.¹⁵ This requirement was lifted in 2021 to allow prescribing to up to 30 patients per clinician without a waiver or additional training by notifying the federal government.¹⁶ The waiver requirement was lifted in December 2022, allowing clinicians to prescribe buprenorphine with a standard US Drug Enforcement Administration prescribing registration number.¹⁷ Recent increases in the availability of clinician training and ongoing support for buprenorphine prescribers may also increase treatment capacity.¹⁰ The objective of this study was to leverage modeling to analyze the cost-effectiveness of interventions and combinations of interventions to expand buprenorphine treatment in the US while considering (1) the tradeoffs of increasing buprenorphine duration, initiation, and capacity and (2) the interaction between the demand for treatment and treatment capacity.

Methods

Model and Interventions

We used the SOURCE model^{[18,19](#)} to estimate the potential public health effects and assess cost-effectiveness of 5 interventions, and their combinations, aimed at increasing OUD treatment with buprenorphine. SOURCE is a system dynamics model that tracks opioid misuse, including OUDs involving prescription opioids and heroin. It models treatment with MOUD, remission, relapse, nonfatal opioid overdose, and OOD. eMethods 1 and eFigure 1 in [Supplement 1](#) present more information about SOURCE. The Mass General Brigham institutional review board exempted the study from review and waived informed consent because the data were not obtained through participant interaction.

We compared 5 interventions: contingency management (CM), psychotherapy, a hub-and-spoke training and support model, emergency department (ED)–initiated buprenorphine, and telehealth for buprenorphine prescribing. Emergency department–initiated buprenorphine entails initiating treatment with MOUD while someone with OUD is in the ED and uses bridge clinics to link them to continued buprenorphine care postdischarge. Contingency management gives patients a voucher, prize, or cash-based incentive for continuing treatment or achieving a negative toxicology screen result.^{[20](#)} Psychotherapy is often paired with MOUD to offer mental health support and may be used to treat underlying mental illness or trauma, while some clinicians require psychotherapy to receive MOUD,^{[21](#)} making it a potential barrier that can decrease duration. Telehealth allows patients taking buprenorphine to meet with health care clinicians through video or phone visits. Policy changes enacted during the COVID-19 pandemic allow greater freedom for clinicians to initiate and continue buprenorphine treatment via telehealth.^{[22](#)} Finally, a hub-and-spoke model increases training and support for clinicians, which uses existing opioid treatment programs that are authorized to prescribe buprenorphine as hubs, while community primary care practices function as the spokes of the program. Patients are referred to the spokes once they are stabilized with treatment with MOUD, while the hubs provide mentorship and training in buprenorphine prescribing.^{[10,23,24](#)}

Literature Review, Effects, and Costs of Interventions

The 5 interventions are associated with increases in the initiation, duration, or capacity of buprenorphine treatment. Emergency department initiation provides support for linking to buprenorphine care, which is followed by increased buprenorphine initiation.^{[7,8](#)} Contingency management encourages patients to continue to receive treatment, which is associated with increased average treatment duration.^{[9](#)} Psychotherapy can encourage patients to continue to receive treatment, but may also serve as a barrier when it is a requirement before receiving buprenorphine, and has an average positive association with increasing duration, but with uncertainty that includes the possibility of shortening duration.^{[9,21](#)} Telehealth is also associated with increased duration by reducing barriers caused by distance and transportation to prescriber offices, allowing people to continue to receive treatment longer.^{[25](#)} Hub-and-spoke models include training and ongoing mentorship to clinicians, and research shows they are associated with an increased total number of prescribers and number of patients per prescriber.^{[10,23,24,25](#)}

We reviewed the literature for estimates of the association of each intervention with duration, capacity, and initiation and the cost of each intervention (eMethods 2 and eTables 1-6 in [Supplement 1](#)). Based on previous analyses, the model assumed that lifting the X waiver was not associated with a change in initiation, capacity, or duration.^{[26,27,28](#)} We included the type of effect for each intervention (duration,

capacity, and initiation) based on measured effects in the literature and excluded effects that we could not quantify. The cost of hub-and-spoke was estimated per clinician based on program-funding data and the total number of clinicians included in the program (eMethods 3 in [Supplement 1](#)).²³ Telehealth is estimated to reduce costs compared with in-person visits.²⁹ These cost reductions are for clinicians (eg, by better time allocation) and patients (eg, by removing the burden of travel, which patients often report as a barrier to MOUD treatment).³⁰ Studies have found telehealth to have lower costs than in-person appointments for various appointment types (eTable 7 in [Supplement 1](#)). We made a conservative assumption of no cost savings for telehealth compared with in-person visits. Costs of the other interventions were based on the literature ([Table 1](#) [7,9,10,13,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50](#); eMethods 3 in [Supplement 1](#)) and adjusted for inflation to 2021 USD.

Projecting the Effects of Interventions

Using SOURCE, we projected the status quo of current buprenorphine prescribing and the associated health outcomes using the same parameters of previous analyses.^{18,19} We then analyzed the status quo, each intervention alone, and all combinations of interventions, a total of 32 strategies, based on the estimated association of these strategies with buprenorphine treatment initiation, capacity, and duration (eTable 8 in [Supplement 1](#)).

To simulate a proportion of the population who would feasibly receive a given intervention on a national scale, we assumed a coverage level of 10% of the total number of patients and prescribers affected by each strategy. The assumption of 10% intervention coverage was based on expert opinion and is subject to the scenario analyses. We assumed a 3-year linear ramp-up period for each strategy's coverage starting in 2022 and reaching full coverage by 2024. We also assumed that no strategy was associated with buprenorphine diversion for illicit use.

Health States and Outcomes

Total quality-adjusted life years (QALYs) reflect the disutility associated with OUD. We determined the quality-of-life effects of treatment from a literature search³⁴ ([Table 1](#)) and applied QALYs to the number of people in each health state in SOURCE as stratified by type of opioid use, treatment status, and remission status. We projected the effectiveness of each intervention during a 12-year horizon (2021-2032) with lifetime follow-up, which includes average lifetime QALYs and costs expected for each person remaining in the model after 2032 as based on the age-weighted quality-adjusted life expectancy ([Table 1](#); eMethods 4 in [Supplement 1](#)). We estimated total nonfatal opioid overdoses, OODs, and QALYs and compared these health outcomes with the status quo of no additional interventions.^{18,19}

Cost-effectiveness Analysis

In the primary cost-effectiveness analysis, we took a societal perspective. Total costs included background and excess health care costs by OUD and treatment status, treatment costs, criminal justice costs, and intervention costs based on the number of people in each health state ([Table 1](#); eMethods 5 and 6 in [Supplement 1](#)). For each overdose death, the age-weighted lost net productivity (ie, the expected productivity for each person minus the expected consumption during the remainder of their lifetime) was included.⁵¹

For each strategy, we calculated average costs and QALYs for each health and treatment state and costs for each intervention ([Table 1](#)), applying an annual discount rate of 3% for all costs and QALYs.⁵² We calculated the incremental cost-effectiveness ratios (ICERs) for each strategy by calculating the incremental costs divided by incremental QALYs compared with the strategy with the next lowest cost. Strategies were considered dominated if they were more expensive and less effective than alternative strategies. We compared the resulting ICERs with a range of willingness-to-pay thresholds up to \$200 000/QALY gained, for which strategies are generally considered to be cost-effective in the US.^{53,54,55} We followed the Consolidated Health Economic Evaluation Reporting Standards ([CHEERS](#)) reporting guideline.⁵⁶

Sensitivity Analysis

We conducted a probabilistic sensitivity analysis to vary the effectiveness and costs of each of the interventions and the costs of MOUD ([Table 1](#)) for 1000 runs using uniform distributions. Costs were varied 25% from the base case. To compare the interventions, the incremental net monetary benefit was calculated with a willingness to pay of \$100 000/QALY gained. Interventions with positive net monetary benefits were considered cost-effective compared with the status quo, and those with the highest incremental net monetary benefit were considered the preferred strategy.

Health Care Perspective and Scenario Analysis

We compared the base case results from a societal perspective with those from the health care perspective, which excludes criminal justice, productivity, and consumption costs. We also compared the results of the cost-effectiveness assessment by estimating the effect of varying intervention coverage from 10% to 5% and 20% for each intervention. eMethods 7 in [Supplement 1](#) presents the estimation process.

Study Timeline and Data Use

The analysis was conducted from March 2021 through March 2023. Data inputs were based on published literature or on the previously calibrated and validated SOURCE model. Vensim DSS (Ventana Systems) was used for the simulation analysis and R (R Foundation) was used to calculate the cost-effectiveness results.

Results

Health Outcomes

In the status quo, SOURCE projected 7 593 200 nonfatal and 668 424 fatal opioid overdoses from 2021 to 2032. We estimated that buprenorphine treatment is currently capacity constrained (patient demand exceeds available care). Within the status quo, we projected that, due to a declining trend in the total number of people with OUD,^{18,19} buprenorphine treatment demand will decrease²⁸ and no longer be capacity constrained as of 2024 (eFigure 2 in [Supplement 1](#)).

[Figure 1](#) presents the projected trends of overdose deaths compared with the status quo from 2021, 1 year before the interventions, to 2032. Starting in 2026, the expansion of CM services for buprenorphine averted the most annual overdose deaths compared with any other single-intervention strategies, after increasing deaths initially due to increased demand, which constrained the limited available ca-

capacity ([Figure 1A](#)). Expansion of the hub-and-spoke model initially predicted an increase in overdose deaths averted, which declined to 0 as capacity became less constrained. Contingency management, which was operationalized with an increase in the average treatment duration of 7% with a coverage level of 10% of patients with buprenorphine, was associated with more deaths than the status quo from 2021 to 2025, when buprenorphine treatment capacity was limited, because patients received treatment longer, decreasing the capacity available for new patients to initiate treatment with buprenorphine. Implementing interventions associated with increased capacity alongside interventions associated with increased treatment duration was followed by more deaths averted and no initial increase in deaths ([Figure 1B](#)).

From 2021 to 2032, CM had the largest health benefit of all the single-intervention strategies, averting 3530 fatal overdoses ([Table 1](#)) and gaining 182 127 QALYs ([Table 2](#)) compared with the status quo. The least beneficial single-intervention strategy was the expansion of psychotherapy, which was estimated to avert 80 overdose deaths ([Table 1](#)) and gain 4238 QALYs. The combination of all 5 interventions averted 8570 overdose deaths ([Table 1](#)) and gained 520 557 QALYs, the most of any strategy combination ([Table 2](#)).

Important effects from the combinations of interventions were captured by the model ([Table 2](#)). The strategy of telehealth and hub-and-spoke averted 3690 fatal overdoses, more than adding the respective fatal overdoses averted of telehealth (2420) and hub-and-spoke (940), showing a synergy when increasing duration and capacity. The strategy of CM and telehealth averted fewer fatal overdoses (5390) than the sum of overdose deaths averted by CM (3530) and telehealth (2420), suggesting diminishing returns when implementing interventions that increase duration without also increasing capacity.

Expected Costs and Cost-effectiveness

[Table 3](#) shows cost-effectiveness results for all strategies. The portfolio of psychotherapy and hub-and-spoke was the strategy with the highest costs, and the portfolio of all interventions had the most QALYs gained. For any willingness-to-pay threshold between \$20 000 to \$200 000/QALY gained, the strategy with CM, hub-and-spoke, ED initiation, and telehealth was the preferred strategy with an ICER of \$19 381/QALY gained ([Table 3](#)).

Emergency department initiation + telehealth + CM, CM + hub-and-spoke + ED initiation + telehealth, and the strategy with all 5 interventions were along the cost-effectiveness frontier ([Figure 2](#)). Ten strategies were cost-saving compared with the status quo, as they had greater health benefits with lower total costs than the status quo.

Sensitivity Analysis

Cost-effectiveness results were robust across uncertainty ranges. When considering a range of effectiveness in 1000 simulation runs, 10 strategies were cost-effective compared with the status quo in 100% of runs with a willingness-to-pay threshold of \$100 000 per QALY gained (eTable 9 in [Supplement 1](#)). The combination of CM, hub-and-spoke, ED initiation, and telehealth was the preferred intervention in 66% of probabilistic sensitivity analysis runs and the combination of all interventions was preferred in 34% of runs. Apart from psychotherapy alone and the combination of psychotherapy with hub-and-spoke, all other strategies were cost-effective compared with the status quo for any willingness-to-pay threshold of less than \$100 000/QALY gained for at least 70% of runs. The combination

of CM, ED initiation, and telehealth was preferred most often for a willingness-to-pay threshold less than \$16 500, and the combination of CM, hub-and-spoke, ED initiation, and telehealth was preferred most often greater than that threshold (eFigure 3 in [Supplement 1](#)).

Health Care Perspective and Scenario Analysis

When we considered only the health care perspective, the strategy with CM, hub-and-spoke, ED initiation, and telehealth remained the preferred strategy for any willingness-to-pay threshold between \$30 000 to \$200 000/QALY gained, with an ICER of \$29 514/QALY gained (eTable 10 in [Supplement 1](#)). Emergency department initiation remained cost-saving compared with the status quo in the health care perspective.

When comparing the results of an expansion of 10% coverage to 5% and 20% for all interventions, the number of overdose deaths averted increased with increasing intervention coverage, but it was less as the rate of coverage level increased (eTable 11 in [Supplement 1](#)). For example, the strategy with all interventions averted 4360 overdose deaths with 5% coverage and 8570 overdose deaths with 10% coverage and averted 16 620 overdose deaths for 20% coverage (eTable 11 in [Supplement 1](#)). The strategy with CM, hub-and-spoke, ED initiation, and telehealth remained the preferred strategy, with an ICER of \$27 776/QALY gained for a coverage level of 5% and \$11 531/QALY gained for a coverage level of 20% (eTables 12 and 13 in [Supplement 1](#)).

Discussion

In this economic evaluation study that projected health outcomes and cost-effectiveness from 2021 to 2032, we found that a combination of strategies, including CM, hub-and-spoke clinician training, ED buprenorphine initiation, and telehealth was the preferred strategy at a generally accepted threshold and was likely to be cost-saving compared with the status quo. In sensitivity analyses, several combinations of interventions associated with increased buprenorphine treatment duration, capacity, and treatment initiation were considered cost-effective vs a plausible range of parameter values. Many strategies were cost-effective or cost-saving compared with the status quo, illustrating that various policy options associated with increased buprenorphine treatment and improved health outcomes are preferable compared with current treatment levels.

Although CM and telehealth were projected to be effective in increasing treatment duration, this strategy could be associated with an initial increase in overdose deaths due to treatment capacity constraints. However, when strategies combined interventions that were associated with increased treatment duration and capacity, there was a decrease in overdose deaths, and the benefits were greater than the sum of the 2 separate interventions, indicating the importance of increasing duration and capacity simultaneously. On the other hand, only increasing capacity through the hub-and-spoke training had a limited effect and only averted overdose deaths when buprenorphine treatment capacity was constrained. The greatest effects were seen when implementing multimodal strategies that simultaneously addressed buprenorphine initiation, duration, and capacity. These results demonstrate the importance of including treatment capacity and utilization in a care model to capture this dynamic.

The study results rely on the projections of SOURCE, which predicts changes in opioid use patterns and treatment demand.[18,19,57](#) If the national demand for buprenorphine treatment decreases over time, as SOURCE predicts, interventions to expand capacity may only be needed in the next 4 to 6 years. If demand for buprenorphine treatment does not decrease, contrary to the SOURCE projections, or with

the expansion of interventions associated with increased demand, hub-and-spoke interventions may be more effective and cost-effective than we have estimated, as it will increase capacity when it is constrained, especially when included in portfolios with interventions associated with increased treatment duration.

We demonstrated the effects of changes to buprenorphine treatment, only one of many potential options to treat OUD. In the main analysis, we considered a 10% coverage level of all interventions, demonstrating a potential to avert 8570 overdose deaths when implementing interventions. However, the study results suggest that even though the number of deaths averted was small, substantial QALYs are gained from strategies associated with increased buprenorphine treatment initiation, duration, and capacity. Furthermore, 10 strategies were cost-saving compared with the status quo in the societal perspective and 1 in the health care perspective, which shows that many combinations of interventions may improve health outcomes and avert more downstream costs than the initial investments required for the intervention.

Limitations

This study was subject to limitations, including the limitations of the SOURCE model.^{18,19} We only included interventions associated with buprenorphine duration, capacity, and initiation based on quantitative evidence in the literature. Interventions may have multiple associations with buprenorphine use that were not captured in this analysis, making them potentially even more effective at increasing buprenorphine duration, capacity, and initiation than we have suggested and making the potential for health benefits even greater. Our analysis did not capture the mechanism by which each intervention affects buprenorphine use, and we did not highlight specific barriers that can be addressed by each intervention, such as financial, stigmatic, logistical, or regulatory barriers. This analysis was at the national level and did not consider regional, local, or demographic differences in OUD, buprenorphine capacity, or buprenorphine demand. Estimates of the effectiveness and costs of interventions were based on studies with a smaller scale than nationwide programs. There might be differences in the original study populations, efficiency gains, and scaling costs that we did not consider. Heterogeneity within each health state, including age and sex stratification, was not modeled. We did not compare the feasibility of implementing these strategies, although some may be more difficult to implement on a national scale than others. We lacked data on the interactions between interventions with which to compare model outcomes and how that might change costs and effects when interventions are implemented together. We did not include effects of interventions other than their association with buprenorphine treatment receipt (eg, psychotherapy's association with mental health outcomes). An extension of this work would be to compare buprenorphine-specific interventions with additional OUD interventions, including methadone expansion, providing naloxone for harm reduction, and preventing addiction. Despite these limitations, this study offered potential insights to improve the models of care for OUD treatment.

Conclusions

The study findings potentially add to the literature by considering how interventions affect the initiation, duration, and capacity of buprenorphine treatment using a system dynamics model, including capacity constraints. This is important, as capacity constraints can limit the effectiveness of interventions and even be associated with more deaths initially when increasing duration. The study results are consistent with previous studies that did not include capacity constraints, which found that increasing buprenorphine duration is cost-effective^{11,13} or cost-saving.⁹ However, this study suggested that the most benefit could be gained by implementing strategies that increase buprenorphine capacity and du-

ration simultaneously. Additionally, we estimated that the benefits of increasing buprenorphine duration will be undermined unless capacity is expanded; otherwise, patients who want to initiate treatment may be crowded out by patients remaining in treatment longer.

Notes

Supplement 1.

eMethods 1. Overview of SOURCE model

eMethods 2. Description of literature review process

eMethods 3. Calculating final values for intervention effectiveness and costs

eMethods 4. Methods for calculating expected end-of-life QALYs

eMethods 5. Methods for calculating healthcare costs of opioid use disorder

eMethods 6. Methods for calculating productivity and consumption costs

eMethods 7. Sensitivity analysis process

eFigure 1. SOURCE's structure

eFigure 2. Buprenorphine effective capacity utilization over time in the status quo

eFigure 3. Cost-effectiveness acceptability curve

eTable 1. Literature search systematic approach

eTable 2. Effectiveness, retention, duration, and costs of contingency management (CM) in MOUD treatment studies

eTable 3. Effectiveness, retention, duration, and costs of psychotherapy and counseling methods in MOUD treatment studies

eTable 4. Provider training

eTable 5. Emergency department initiation of buprenorphine

eTable 6. Telemedicine for buprenorphine appointments

eTable 7. Telemedicine costs for non-buprenorphine appointments

eTable 8. Example model inputs and range for each intervention; 20% coverage level

eTable 9. Sensitivity analysis - average incremental costs, QALYs gained, and net monetary benefit (NMB) by intervention compared to the status quo, 10% intervention coverage

eTable 10. Expected intervention costs, QALYs, and cost per QALY gained for each strategy; healthcare perspective only, 10% coverage

eTable 11. Expected overdose deaths for each strategy, with varying coverage interventions

eTable 12. Expected intervention costs, QALYs, and cost per QALY gained for each strategy; 5% coverage of all interventions

eTable 13. Expected intervention costs, QALYs, and cost per QALY gained for each strategy; 20% coverage of all interventions

eTable 14. Quality-adjusted life years for each health state in SOURCE

Supplement 2.

Data sharing statement

References

1. US Centers for Disease Control and Prevention . Mortality data on CDC WONDER. Accessed September 29, 2021. <https://wonder.cdc.gov/mcd.html>
2. National Center for Health Statistics . Drug overdose deaths in the U.S. top 100,000 annually. Accessed July 5, 2022. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm
3. Substance Abuse and Mental Health Services Administration . 2019 National survey on drug use and health public use file codebook. Accessed September 9, 2022. <https://www.datafiles.samhsa.gov/sites/default/files/field-uploads-protected/studies/NSDUH-2019/NSDUH-2019-datasets/NSDUH-2019-DS0001/NSDUH-2019-DS0001-info/NSDUH-2019-DS0001-info-codebook.pdf>
4. Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. *Drug Alcohol Depend.* 2019;197:78-82. doi: 10.1016/j.drugalcdep.2018.12.030 [PubMed: 30784952] [CrossRef: 10.1016/j.drugalcdep.2018.12.030]
5. Beaulieu E, DiGennaro C, Stringfellow E, et al.. Economic evaluation in opioid modeling: systematic review. *Value Health.* 2021;24(2):158-173. doi: 10.1016/j.jval.2020.07.013 [PMCID: PMC7864393] [PubMed: 33518022] [CrossRef: 10.1016/j.jval.2020.07.013]
6. Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. *Am J Prev Med.* 2018;54(6)(suppl 3):S230-S242. doi: 10.1016/j.amepre.2017.12.022 [PMCID: PMC6330240] [PubMed: 29779547] [CrossRef: 10.1016/j.amepre.2017.12.022]
7. D'Onofrio G, O'Connor PG, Pantalon MV, et al.. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. *JAMA.* 2015;313(16):1636-1644. doi: 10.1001/jama.2015.3474 [PMCID: PMC4527523] [PubMed: 25919527] [CrossRef: 10.1001/jama.2015.3474]
8. Busch SH, Fiellin DA, Chawarski MC, et al.. Cost-effectiveness of emergency department-initiated treatment for opioid dependence. *Addiction.* 2017;112(11):2002-2010. doi: 10.1111/add.13900 [PMCID: PMC5657503] [PubMed: 28815789] [CrossRef: 10.1111/add.13900]
9. Fairley M, Humphreys K, Joyce VR, et al.. Cost-effectiveness of treatments for opioid use disorder. *JAMA Psychiatry.* 2021;78(7):767-777. doi: 10.1001/jamapsychiatry.2021.0247 [PMCID: PMC8014209] [PubMed: 33787832] [CrossRef: 10.1001/jamapsychiatry.2021.0247]
10. Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. *J Addict Med.* 2017;11(4):286-292. doi: 10.1097/ADM.0000000000000310 [PMCID: PMC5537005] [PubMed: 28379862] [CrossRef: 10.1097/ADM.0000000000000310]

11. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. *Addiction*. 2001;96(9):1267-1278. doi: 10.1046/j.1360-0443.2001.96912676.x [PubMed: 11672491] [CrossRef: 10.1046/j.1360-0443.2001.96912676.x]
12. Rao IJ, Humphreys K, Brandeau ML. Effectiveness of policies for addressing the US opioid epidemic: a model-based analysis from the Stanford-Lancet Commission on the North American Opioid Crisis. *Lancet Reg Health Am*. 2021;3:100031. Published online July 31, 2021. [PMCID: PMC8592267] [PubMed: 34790907]
13. Krebs E, Enns B, Evans E, et al.. Cost-effectiveness of publicly funded treatment of opioid use disorder in California. *Ann Intern Med*. 2018;168(1):10-19. doi: 10.7326/M17-0611 [PubMed: 29159398] [CrossRef: 10.7326/M17-0611]
14. Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. *Am J Public Health*. 2018;108(10):1394-1400. doi: 10.2105/AJPH.2018.304590 [PMCID: PMC6137764] [PubMed: 30138057] [CrossRef: 10.2105/AJPH.2018.304590]
15. 114th Congress . Comprehensive Addiction and Recovery Act of 2016. Accessed October 2, 2022. <https://www.congress.gov/114/plaws/publ198/PLAW-114publ198.pdf>
16. Stringfellow EJ, Humphreys K, Jalali MS. Removing the x-waiver is one small step toward increasing treatment of opioid use disorder, but great leaps are needed. Accessed April 1, 2023. doi: 10.1377/hblog20210419.311749 [CrossRef: 10.1377/hblog20210419.311749]
17. 117th Congress . H.R.2617—Consolidated Appropriations Act, 2023. Accessed April 1, 2023. <https://www.congress.gov/bill/117th-congress/house-bill/2617>
18. Lim TY, Stringfellow EJ, Stafford CA, et al.. Modeling the evolution of the US opioid crisis for national policy development. *Proc Natl Acad Sci U S A*. 2022;119(23):e2115714119. doi: 10.1073/pnas.2115714119 [PMCID: PMC9191351] [PubMed: 35639699] [CrossRef: 10.1073/pnas.2115714119]
19. Stringfellow EJ, Lim TYL, Humphreys K, et al.. Reducing opioid use disorder and overdose deaths in the United States: a dynamic modeling analysis. *Sci Adv*. 2022;8(25):eabm8147. doi: 10.1126/sciadv.abm8147 [PMCID: PMC9232111] [PubMed: 35749492] [CrossRef: 10.1126/sciadv.abm8147]
20. Petry NM. Contingency management: what it is and why psychiatrists should want to use it. *Psychiatrist*. 2011;35(5):161-163. doi: 10.1192/pb.bp.110.031831 [PMCID: PMC3083448] [PubMed: 22558006] [CrossRef: 10.1192/pb.bp.110.031831]
21. Burns RM, Pacula RL, Bauhoff S, et al.. Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013. *Subst Abuse*. 2016;37(1):63-69. doi: 10.1080/08897077.2015.1080208 [PMCID: PMC4801690] [PubMed: 26566761] [CrossRef: 10.1080/08897077.2015.1080208]
22. Lin LA, Zhang L, Kim HM, Frost MC. Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder. *Am J Psychiatry*. 2022;179(10):740-747. doi: 10.1176/appi.ajp.21111141 [PMCID: PMC9529783] [PubMed: 35899380] [CrossRef: 10.1176/appi.ajp.21111141]
23. Reif S, Brolin MF, Stewart MT, Fuchs TJ, Speaker E, Mazel SB. The Washington State hub and spoke model to increase access to medication treatment for opioid use disorders. *J Subst Abuse Treat*. 2020;108:33-39. doi: 10.1016/j.jsat.2019.07.007 [PMCID: PMC6893117] [PubMed: 31358328] [CrossRef: 10.1016/j.jsat.2019.07.007]
24. Winstanley EL, Lander LR, Berry JH, et al.. West Virginia's model of buprenorphine expansion: preliminary results. *J Subst Abuse Treat*. 2020;108:40-47. doi: 10.1016/j.jsat.2019.05.005 [PMCID: PMC7055678] [PubMed: 31221524] [CrossRef: 10.1016/j.jsat.2019.05.005]
25. Lin LA, Fortney JC, Bohnert ASB, Coughlin LN, Zhang L, Piette JD. Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder. *J Subst Abuse Treat*. 2022;133:108492. doi: 10.1016/j.jsat.2021.108492 [PMCID: PMC8627529] [PubMed: 34175175] [CrossRef: 10.1016/j.jsat.2021.108492]

26. Haffajee RL, Andracka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. *Subst Abuse Treat Prev Policy*. 2020;15(1):69. doi: 10.1186/s13011-020-00312-3 [PMCID: PMC7491096] [PubMed: 32928272] [CrossRef: 10.1186/s13011-020-00312-3]
27. Winograd RP, Coffey B, Woolfolk C, et al.. To prescribe or not to prescribe?: barriers and motivators for progressing along each stage of the buprenorphine training and prescribing path. *J Behav Health Serv Res*. 2023;50(2):165-180. doi: 10.1007/s11414-021-09783-z [PubMed: 35060002] [CrossRef: 10.1007/s11414-021-09783-z]
28. Stringfellow EJ, Lim TY, DiGennaro C, et al.. Long-term effects of increasing buprenorphine treatment seeking, duration, and capacity on opioid overdose fatalities: a model-based analysis. *J Addict Med*. Published online February 28, 2023. doi: 10.1097/ADM.0000000000001153 [PMCID: PMC10460819] [PubMed: 36799870] [CrossRef: 10.1097/ADM.0000000000001153]
29. Guillen AG, Reddy M, Saadat S, Chakravarthy B. Utilization of telehealth solutions for patients with opioid use disorder using buprenorphine: a scoping review. *Telemed J E Health*. 2022;28(6):761-767. [PubMed: 34714172]
30. Hughto JMW, Peterson L, Perry NS, et al.. The provision of counseling to patients receiving medications for opioid use disorder: telehealth innovations and challenges in the age of COVID-19. *J Subst Abuse Treat*. 2021;120:108163. doi: 10.1016/j.jsat.2020.108163 [PMCID: PMC7545305] [PubMed: 33298301] [CrossRef: 10.1016/j.jsat.2020.108163]
31. Jennings LK, Lane S, McCauley J, et al.. Retention in treatment after emergency department-initiated buprenorphine. *J Emerg Med*. 2021;61(3):211-221. doi: 10.1016/j.jemermed.2021.04.007 [PMCID: PMC8628549] [PubMed: 34176686] [CrossRef: 10.1016/j.jemermed.2021.04.007]
32. Kaucher KA, Caruso EH, Sungar G, et al.. Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program. *Am J Emerg Med*. 2020;38(2):300-304. doi: 10.1016/j.ajem.2019.158373 [PubMed: 31387811] [CrossRef: 10.1016/j.ajem.2019.158373]
33. Bogan C, Jennings L, Haynes L, et al.. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state. *J Subst Abuse Treat*. 2020;112S:73-78. doi: 10.1016/j.jsat.2020.02.007 [PMCID: PMC8115203] [PubMed: 32220414] [CrossRef: 10.1016/j.jsat.2020.02.007]
34. Wittenberg E, Bray JW, Aden B, Gebremariam A, Nosyk B, Schackman BR. Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population. *Addiction*. 2016;111(4):675-684. doi: 10.1111/add.13219 [PMCID: PMC5034732] [PubMed: 26498740] [CrossRef: 10.1111/add.13219]
35. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. *Med Decis Making*. 2006;26(4):410-420. doi: 10.1177/0272989X06290495 [PMCID: PMC2634296] [PubMed: 16855129] [CrossRef: 10.1177/0272989X06290495]
36. US Census Bureau . Current population survey, annual social and economic supplement. Accessed August 1, 2021. https://www2.census.gov/programs-surveys/demo/tables/age-and-sex/2019/older-population/2019older_table1.xlsx
37. Arias E, Xu J. United States life tables, 2018. Accessed August 3, 2021. <https://www.cdc.gov/nchs/data/nvsr/nvsr69/nvsr69-12-508.pdf>
38. Office of the Secretary, US Department of Defense . Tricare; mental health and substance use disorder treatment: final rule. *Fed Regist*. 2016;81(171):61067-61098. [PubMed: 27592499]
39. Linas BP, Savinkina A, Madushani RWMA, et al.. Projected estimates of opioid mortality after community-level interventions. *JAMA Netw Open*. 2021;4(2):e2037259. doi: 10.1001/jamanetworkopen.2020.37259 [PMCID: PMC7885041] [PubMed: 33587136] [CrossRef: 10.1001/jamanetworkopen.2020.37259]

40. Mitchell EM. Concentration of healthcare expenditures and selected characteristics of high spenders, US civilian noninstitutionalized population, 2018. Accessed June 1, 2021. https://meps.ahrq.gov/data_files/publications/st533/stat533.pdf [PubMed: 35696507]
41. Baser O, Xie L, Mardekian J, Schaaf D, Wang L, Joshi AV. Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration. *Pain Pract.* 2014;14(5):437-445. doi: 10.1111/papr.12097 [PubMed: 23809020] [CrossRef: 10.1111/papr.12097]
42. Kirson NY, Shei A, Rice JB, et al.. The burden of undiagnosed opioid abuse among the commercially insured. *Pain Med.* 2015;16(7):1325-1332. doi: 10.1111/pme.12768 [PubMed: 25929289] [CrossRef: 10.1111/pme.12768]
43. Jiang Y, McDonald JV, Koziol J, McCormick M, Viner-Brown S, Alexander-Scott N. Can emergency department, hospital discharge, and death data be used to monitor burden of drug overdose in Rhode Island? *J Public Health Manag Pract.* 2017;23(5):499-506. doi: 10.1097/PHH.0000000000000514 [PubMed: 28009694] [CrossRef: 10.1097/PHH.0000000000000514]
44. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. *Ann Intern Med.* 2013;158(1):1-9. doi: 10.7326/0003-4819-158-1-201301010-00003 [PubMed: 23277895] [CrossRef: 10.7326/0003-4819-158-1-201301010-00003]
45. Behrends CN, Paone D, Nolan ML, et al.. Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City. *J Subst Abuse Treat.* 2019;106:79-88. doi: 10.1016/j.jsat.2019.08.010 [PubMed: 31540615] [CrossRef: 10.1016/j.jsat.2019.08.010]
46. Premier Inc . Opioid overdoses costing U.S. hospitals an estimated \$11 billion annually. Accessed June 27, 2021. <https://www.premierinc.com/newsroom/press-releases/opioid-overdoses-costing-u-s-hospitals-an-estimated-11-billion-annually>
47. Murphy SM, McCollister KE, Leff JA, et al.. Cost-effectiveness of buprenorphine–naloxone versus extended-release naltrexone to prevent opioid relapse. *Ann Intern Med.* 2019;170(2):90-98. doi: 10.7326/M18-0227 [PMCID: PMC6581635] [PubMed: 30557443] [CrossRef: 10.7326/M18-0227]
48. US Census Bureau . Current population survey 2020. annual social and economic (ASEC) supplement. Accessed June 1, 2021. <https://www2.census.gov/programs-surveys/cps/techdocs/cpsmar20.pdf>
49. US Bureau of Labor Statistics . Consumer expenditures report, 2019. Accessed July 14, 2021. <https://www.bls.gov/opub/reports/consumer-expenditures/2019/home.htm#:~:text=Average%20annual%20expenditures%20increased%203.0,increase%20from%202017%20to%202018.>
50. Vakkalanka JP, Lund BC, Ward MM, et al.. Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: a retrospective cohort study of US veterans. *J Gen Intern Med.* 2022;37(7):1610-1618. doi: 10.1007/s11606-021-06969-1 [PMCID: PMC8219175] [PubMed: 34159547] [CrossRef: 10.1007/s11606-021-06969-1]
51. Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE. *Cost-Effectiveness in Health and Medicine*. Oxford University Press; 2016.
52. Basu A, Ganiats TG. Discounting in Cost-Effectiveness Analysis. In: *Cost-Effectiveness in Health and Medicine*. Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, eds. Oxford University Press; 2016:277-288. doi: 10.1093/acprof:oso/9780190492939.003.0010 [CrossRef: 10.1093/acprof:oso/9780190492939.003.0010]
53. Prosser LA, Neumann PJ, Sanders GD, Siegel JE. Reporting Cost-Effectiveness Analyses. In: *Cost-Effectiveness in Health and Medicine*. Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, eds. Oxford University Press; 2016:343-368. doi: 10.1093/acprof:oso/9780190492939.003.0013 [CrossRef: 10.1093/acprof:oso/9780190492939.003.0013]

54. McDougall JA, Furnback WE, Wang BCM, Mahlich J. Understanding the global measurement of willingness to pay in health. *J Mark Access Health Policy*. 2020;8(1):1717030. doi: 10.1080/20016689.2020.1717030 [PMCID: PMC7048225] [PubMed: 32158523] [CrossRef: 10.1080/20016689.2020.1717030]

55. World Health Organization . Making choices in health: WHO guide to cost-effectiveness analysis. Accessed June 27, 2022. <https://agris.fao.org/agris-search/search.do?recordID=XF2015015286>

56. Husereau D, Drummond M, Petrou S, et al.; CHEERS Task Force . Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMJ*. 2013;346:f1049. doi: 10.1136/bmj.f1049 [PubMed: 23529982] [CrossRef: 10.1136/bmj.f1049]

57. Stringfellow EJ, Lim TY, DiGennaro C, Hasgul Z, Jalali MS. Enumerating contributions of fentanyl and other factors to the unprecedented 2020 rise in opioid overdose deaths: model-based analysis. *Proc Natl Acad Sci U S A Nexus*. Published online March 3, 2023 doi: 10.1093/pnasnexus/pgad064 [PMCID: PMC10069612] [PubMed: 37020497] [CrossRef: 10.1093/pnasnexus/pgad064]

Figures and Tables

Table 1.

Parameter Values and Sources

Parameter	Value (uncertainty range)	Source
Intervention effectiveness^a		
Initiation		
Emergency department buprenorphine initiation: relative rate of buprenorphine treatment initiation	1.556 (1.164-2.108)	7,31,32,33
Duration		
Contingency management: hazard rate ratio of buprenorphine discontinuation	0.594 (0.437-0.787)	9
Psychotherapy: hazard rate ratio of buprenorphine discontinuation	0.986 (0.772-1.240)	9
Telehealth: hazard rate ratio of buprenorphine discontinuation	0.69 (0.60-0.78)	50
Capacity		
Hub-and-spoke: percentage increase in the total number of clinicians ^b	64%	10
Hub-and-spoke: percentage increase in the number of patients per clinician ^b	50%	10
Intervention coverage (percentage of population covered by intervention)	10% (5%-20%)	Assumed
QALYs for each health state^c		
Nondisordered heroin use	0.574 (0.538-0.611)	34
Rx misuse, no heroin use in the past year	0.694 (0.660-0.727)	34
Rx OUD, no heroin use in the past year, no MOUD	0.626 (0.591-0.661)	34
Rx OUD with heroin use in the past year, no MOUD	0.569 (NA)	Calculated
HUD no MOUD	0.512 (0.475-0.549)	34
Rx OUD or HUD in MOUD treatment	0.7660 (0.7395-0.7925)	34
Rx OUD or HUD in remission	0.807 (0.78-0.834)	34
Average additional QALYs for lifetime follow-up	22.64	35,36,37
Costs (2021 USD)^d		
Cost of hub-and-spoke training program per clinician in the network ^e	34 558	23
Contingency management per patient year ^e	3578 (2684-4473)	9
Psychotherapy per patient year ^e	4540 (3405-5675)	2,38
Emergency department-initiated buprenorphine per patient ^e	558 (418-697)	8,39
Telehealth per patient	0	Assumed ^f
Annual background health care costs	6063	40
Annual excess cost of health care utilization with OUD: out of treatment	7598	41
Annual excess cost of health care utilization with OUD: in treatment	6078	9,41,42

Abbreviations: HUD, opioid use disorder involving heroin; MOUD, medication for opioid use disorder; NA, not applicable; OUD, opioid use disorder; Rx OUD, opioid use disorder involving prescription opioids; QALY, quality-adjusted life-year.

^a Further details on intervention effectiveness as applied in SOURCE are included in eTable 8 in [Supplement 1](#). All other parameters were previously published.¹⁹

^b Hub-and-spoke capacity effects and uncertainty ranges were converted for input into the model (eTable 8 in [Supplement 1](#)).

^c Detailed QALYs per health state are included in eTable 14 in [Supplement 1](#).


^d Adjusted for inflation to reflect 2021 USD using the Consumer Price Index.

^e Uncertainty range based on a 25% range more or less than the base case value.

^f Telehealth cost is estimated to be 0 based on the conservative assumption that it will not save costs (eMethods 3 and eTable 7 in [Supplement 1](#)).

^g Criminal justice costs include the price of incarceration.

Figure 1.



Overdose Deaths Averted Compared With the Status Quo, 2021-2032

Line graphs that show the overdose deaths averted, calculated by the number of overdose deaths in the status quo subtracted by the number of overdoses for each intervention, each year from 2021 to 2032. A, Single-intervention strategies. B, Portfolio strategies with 4 or more interventions. ED indicates emergency department initiation.

Table 2.

Cumulative Expected Health Outcomes and Comparison With the Status Quo From 2021 to 2032

Strategy	Total nonfatal opioid overdoses, 2021-2032	Total nonfatal opioid overdoses averted ^a	Total fatal opioid overdoses, 2021-2032	Total opioid overdose deaths averted ^a
SQ	7 593 200	0	668 424	0
Single-intervention strategies				
CM	7 562 800	30 400	664 894	3530
P	7 592 500	700	668 344	80
HS	7 584 200	9000	667 484	940
ED	7 583 200	10 000	667 314	1110
TH	7 572 300	20 900	666 004	2420
Strategies with multiple interventions				
CM+P	7 562 200	31 000	664 834	3590
CM+HS	7 548 400	44 800	663 374	5050
P+HS	7 583 500	9700	667 394	1030
CM+P+HS	7 547 700	45 500	663 294	5130
CM+ED	7 554 000	39 200	663 924	4500
HS+ED	7 573 600	19 600	666 294	2130
P+ED	7 582 600	10 600	667 234	1190
CM+P+ED	7 553 500	39 700	663 864	4560
CM+HS+ED	7 538 300	54 900	662 254	6170
P+HS+ED	7 572 800	20 400	666 214	2210
CM+P+HS+ED	7 537 600	55 600	662 174	6250
CM+TH	7 546 800	46 400	663 034	5390
P+TH	7 571 700	21 500	665 934	2490
HS+TH	7 560 200	33 000	664 734	3690
ED+TH	7 563 100	30 100	664 984	3440
CM+P+TH	7 546 400	46 800	662 984	5440
CM+HS+TH	7 527 400	65 800	660 964	7460
P+HS+TH	7 559 500	33 700	664 644	3780
CM+ED+TH	7 538 900	54 300	662 164	6260
HS+ED+TH	7 549 900	43 300	663 584	4840
P+ED+TH	7 562 600	30 600	664 914	3510
CM+P+ED+TH	7 538 500	54 700	662 104	6320

Abbreviations: CM, contingency management; ED, emergency department initiation; HS, hub and spoke; P, psychotherapy; SQ, status quo; TH, telehealth; QALYs, quality-adjusted life-years.

^a Nonfatal and fatal overdoses averted compared with the status quo of no intervention.

Table 3.


Expected Intervention QALYs, Costs, and ICER From 2021 to 2032

Strategy	QALYs gained compared with SQ	Total QALYs	Incremental cost compared with SQ (2021 USD)	Total cost (2021 USD)	ICER (2021 USD per QALY gained) ^a
CM+ED+TH	341 400	236 273 859	−2 782 819 715	1 568 705 665 750	ND
ED+TH	209 558	236 142 017	−2 435 967 847	1 569 052 517 617	D
CM+TH	269 948	236 202 407	−2 144 103 592	1 569 344 381 873	D
TH	126 866	236 059 326	−1 695 331 982	1 569 793 153 483	D
CM+ED	260 774	236 193 233	−1 531 093 743	1 569 957 391 722	D
CM	182 127	236 114 587	−825 495 129	1 570 662 990 336	D
ED	89 696	236 022 155	−807 012 013	1 570 681 473 452	D
CM+P+ED+TH	343 508	236 275 967	−722 016 921	1 570 766 468 544	Ex.D
P+ED+TH	212 716	236 145 176	−395 941 485	1 571 092 543 980	D
CM+P+TH	272 254	236 204 714	−80 729 974	1 571 407 755 491	D
SQ	0	235 932 459	0	1 571 488 485 465	D
P+TH	130 344	236 062 803	340 749 222	1 571 829 234 687	D
CM+P+ED	263 770	236 196 230	520 045 349	1 572 008 530 814	D
CM+HS+ED+TH	517 045	236 449 504	621 365 463	1 572 109 850 928	19 381
P+ED	93 729	236 026 188	1 214 388 568	1 572 702 874 033	D
CM+P	185 185	236 117 644	1 222 085 215	1 572 710 570 680	D

Abbreviations: CM, contingency management; D, dominated; ED, emergency department initiation; Ex.D, extended dominance; HS, hub and spoke; ICER, incremental cost-effectiveness ratio; ND, not dominated; P, psychotherapy; SQ, status quo; TH, telehealth.

^a Strategies that are D are more costly and less effective than ND strategies. Strategies that are dominated by extension are more costly and less effective than the linear scale-up ND strategies.

Figure 2.



Cost-effectiveness Plane

The x-axis shows incremental costs compared with the status quo, and the y-axis shows quality-adjusted life-years (QALYs) gained compared with the status quo. Strategies along the line are on the cost-effectiveness frontier and are more efficient than other strategies, as they cost less while having a higher health benefit than alternative strategies. ED indicates emergency department initiation.